Key Highlights
- Bridget Cole appointed as Chief Scientific Officer of 1910 Genetics, bringing over 25 years of drug discovery and development experience.
- Cole’s role will include leading scientific research operations and collaborating with AI leadership to advance 1910 Genetics’ multimodal AI platform.
- Her appointment reflects 1910 Genetics’ commitment to merging technology with biology in drug discovery, targeting neurological, autoimmune diseases, and cancer.
Source: Business Wire
Notable Quotes
- “Our ambition to generate small and large molecule drugs…requires a seasoned but progressive drug developer and team leader like Bridget,” – Jen Nwankwo, Ph.D., Founder and CEO at 1910 Genetics
- “I was drawn to 1910 Genetics because of their unique approach to leveraging both wet lab data and AI methodologies for drug discovery,” – Bridget Cole, Chief Scientific Officer at 1910 Genetics
SoH's Take
The appointment of Bridget Cole as Chief Scientific Officer at 1910 Genetics signifies a strategic move in the biotech industry. Cole’s extensive experience in drug discovery and her leadership in advancing compounds through clinical trials make her an invaluable asset. Her role in integrating AI and biological data in drug discovery is particularly noteworthy. This move by 1910 Genetics underscores the growing trend of leveraging AI in biopharmaceutical research, a step that could revolutionize how we approach drug development, especially for complex diseases like cancer and autoimmune disorders. With Cole’s leadership, 1910 Genetics is poised to make significant contributions to the field, potentially setting new standards for how technology and empirical biology are merged in drug discovery.
